Retroviral delivery of hLPL is not a viable treatment for human hypertriglyceridemia, but these experiments demonstrate that long-term expression of hLPL in skeletal muscle will likely reduce or even eliminate hypertriglyceridemia wherein total absence of LPL is not present. Here, LPL is linked to hypertriglyceridemia.